OBJECTIVE: There is a need for inexpensive noninvasive tests to identify older healthy persons at risk for Alzheimer disease (AD) for enrollment in AD prevention trials. Our objective was to examine whether abnormalities in neuroimaging measures of amyloid and neurodegeneration are correlated with odor identification (OI) in the population-based Mayo Clinic Study of Aging. METHODS: Cognitively normal (CN) participants had olfactory function assessed using the Brief Smell Identification Test (B-SIT), underwent magnetic resonance imaging (n = 829) to assess a composite AD signature cortical thickness and hippocampal volume (HVa), and underwent 11 C-Pittsburgh compound B (n = 306) and 18 fluorodeoxyglucose (n = 305) positron emission tomography scanning to assess amyloid accumulation and brain hypometabolism, respectively. The association of neuroimaging biomarkers with OI was examined using multinomial logistic regression and simple linear regression models adjusted for potential confounders. RESULTS: Among 829 CN participants (mean age = 79.2 years; 51.5% men), 248 (29.9%) were normosmic and 78 (9.4%) had anosmia (B-SIT score < 6). Abnormal AD signature cortical thickness and reduced HVa were associated with decreased OI as a continuous measure (slope = -0.43, 95% confidence interval [CI] = -0.76 to -0.09, p = 0.01 and slope = -0.72, 95% CI = -1.15 to -0.28, p < 0.01, respectively). Reduced HVa, decreased AD signature cortical thickness, and increased amyloid accumulation were significantly associated with increased odds of anosmia. INTERPRETATION: Our findings suggest that OI may be a noninvasive, inexpensive marker for risk stratification, for identifying participants at the preclinical stage of AD who may be at risk for cognitive impairment and eligible for inclusion in AD prevention clinical trials. These cross-sectional findings remain to be validated prospectively. Ann Neurol 2017;81:871-882.
OBJECTIVE: There is a need for inexpensive noninvasive tests to identify older healthy persons at risk for Alzheimer disease (AD) for enrollment in AD prevention trials. Our objective was to examine whether abnormalities in neuroimaging measures of amyloid and neurodegeneration are correlated with odor identification (OI) in the population-based Mayo Clinic Study of Aging. METHODS: Cognitively normal (CN) participants had olfactory function assessed using the Brief Smell Identification Test (B-SIT), underwent magnetic resonance imaging (n = 829) to assess a composite AD signature cortical thickness and hippocampal volume (HVa), and underwent 11 C-Pittsburgh compound B (n = 306) and 18 fluorodeoxyglucose (n = 305) positron emission tomography scanning to assess amyloid accumulation and brain hypometabolism, respectively. The association of neuroimaging biomarkers with OI was examined using multinomial logistic regression and simple linear regression models adjusted for potential confounders. RESULTS: Among 829 CN participants (mean age = 79.2 years; 51.5% men), 248 (29.9%) were normosmic and 78 (9.4%) hadanosmia (B-SIT score < 6). Abnormal AD signature cortical thickness and reduced HVa were associated with decreased OI as a continuous measure (slope = -0.43, 95% confidence interval [CI] = -0.76 to -0.09, p = 0.01 and slope = -0.72, 95% CI = -1.15 to -0.28, p < 0.01, respectively). Reduced HVa, decreased AD signature cortical thickness, and increased amyloid accumulation were significantly associated with increased odds of anosmia. INTERPRETATION: Our findings suggest that OI may be a noninvasive, inexpensive marker for risk stratification, for identifying participants at the preclinical stage of AD who may be at risk for cognitive impairment and eligible for inclusion in AD prevention clinical trials. These cross-sectional findings remain to be validated prospectively. Ann Neurol 2017;81:871-882.
Authors: Matthias H Tabert; Xinhua Liu; Richard L Doty; Michael Serby; Diana Zamora; Gregory H Pelton; Karen Marder; Mark W Albers; Yaakov Stern; D P Devanand Journal: Ann Neurol Date: 2005-07 Impact factor: 10.422
Authors: Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Walter A Rocca Journal: Am J Epidemiol Date: 2011-03-23 Impact factor: 4.897
Authors: Clifford R Jack; Heather J Wiste; Stephen D Weigand; Walter A Rocca; David S Knopman; Michelle M Mielke; Val J Lowe; Matthew L Senjem; Jeffrey L Gunter; Gregory M Preboske; Vernon S Pankratz; Prashanthi Vemuri; Ronald C Petersen Journal: Lancet Neurol Date: 2014-09-04 Impact factor: 44.182
Authors: Grete Kjelvik; Ingvild Saltvedt; Linda R White; Pål Stenumgård; Olav Sletvold; Knut Engedal; Kristina Skåtun; Ann Kristin Lyngvær; Hill Aina Steffenach; Asta K Håberg Journal: BMC Neurol Date: 2014-08-26 Impact factor: 2.474
Authors: Clifford R Jack; Heather J Wiste; David S Knopman; Prashanthi Vemuri; Michelle M Mielke; Stephen D Weigand; Matthew L Senjem; Jeffrey L Gunter; Val Lowe; Brian E Gregg; Vernon S Pankratz; Ronald C Petersen Journal: Neurology Date: 2014-04-04 Impact factor: 9.910
Authors: Nicholas I Woods; Fabio Stefanini; Daniel L Apodaca-Montano; Isabelle M C Tan; Jeremy S Biane; Mazen A Kheirbek Journal: Neuron Date: 2020-04-30 Impact factor: 17.173
Authors: William Charles Kreisl; Peng Jin; Seonjoo Lee; Ezra R Dayan; Shankar Vallabhajosula; Gregory Pelton; José A Luchsinger; Gnanavalli Pradhaban; D P Devanand Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: Qu Tian; Nathalie Chastan; Madhav Thambisetty; Susan M Resnick; Luigi Ferrucci; Stephanie A Studenski Journal: J Am Geriatr Soc Date: 2019-08-23 Impact factor: 7.538
Authors: Xiuli Dan; Noah Wechter; Samuel Gray; Joy G Mohanty; Deborah L Croteau; Vilhelm A Bohr Journal: Ageing Res Rev Date: 2021-07-27 Impact factor: 11.788
Authors: Shannon L Risacher; Eileen F Tallman; John D West; Karmen K Yoder; Gary D Hutchins; James W Fletcher; Sujuan Gao; David A Kareken; Martin R Farlow; Liana G Apostolova; Andrew J Saykin Journal: Alzheimers Dement (Amst) Date: 2017-09-23